Novel anti-inflammatory approaches, such as the antagonists for IL-6 or IL-1β signaling, in addition to antithrombotic treatments, might have a greater effect in preventing thrombosis and death in COVID-19 than either therapy alone [42]. This evidence concerns the gene IL1B and COVID-19.